# 114å¹´ç¬¬äºŒæ¬¡å°ˆé–€è·æ¥­åŠæŠ€è¡“äººå“¡é«˜ç­‰è€ƒè©¦é†«å¸«ä¸­é†«å¸«è€ƒè©¦åˆ†éšæ®µè€ƒè©¦(ç¬¬äºŒéšæ®µè€ƒè©¦) è€ƒå‰çŒœé¡Œ
çŒœé¡Œä¾†æºè‡¨åºŠæ„æŒ‡ä»¥å¯¦ç¿’ç¶“é©—(å«é–€è¨ºåŠä½é™¢)åŠä¸Šèª²å…§å®¹ç‚ºä¸»ä»¥è€ƒå¤é¡ŒåŠ114-2æ–°è€ƒç¶±ç‚ºè¼”ä¹‹çŒœé¡Œ

çŒœé¡Œä¾†æºè€ƒå¤é¡Œæ„æŒ‡ä»¥è€ƒå¤é¡ŒåŠ114-2æ–°è€ƒç¶±ç‚ºä¸»ä»¥å¯¦ç¿’ç¶“é©—(å«é–€è¨ºåŠä½é™¢)åŠä¸Šèª²å…§å®¹ç‚ºè¼”ä¹‹çŒœé¡Œ



## é†«å­¸(ä¸‰)
### å…§ç§‘
#### ä¸€èˆ¬å…§ç§‘
#### å¿ƒè‡Ÿå…§ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
##### ç¼ºè¡€æ€§å¿ƒè‡Ÿç—…
6. Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults ([UpToDate](https://www.uptodate.com/contents/atherosclerotic-cardiovascular-disease-risk-assessment-for-primary-prevention-in-adults))
7. Overview of the acute management of non-ST-elevation acute coronary syndromes ([UpToDate](https://www.uptodate.com/contents/overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes))
##### å¿ƒè‚Œç—‡
8. Major causes of dilated cardiomyopathy ([UpToDate](https://www.uptodate.com/contents/causes-of-dilated-cardiomyopathy?search=dilated%20cardiomyopathy&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1))
##### å¿ƒå¾‹ä¸æ•´
9. 
#### èƒƒè…¸ç§‘
#### è…è‡Ÿç§‘
#### éæ•å…ç–«é¢¨æ¿•ç§‘
#### è…«ç˜¤ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
36. Overview of the classification and management of cancers of unknown primary site ([UpToDate](https://www.uptodate.com/contents/overview-of-the-classification-and-management-of-cancers-of-unknown-primary-site))
37. Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer ([UpToDate](https://www.uptodate.com/contents/overview-of-the-treatment-of-newly-diagnosed-invasive-non-metastatic-breast-cancer))
38. Overview of the initial treatment and prognosis of lung cancer ([UpToDate](https://www.uptodate.com/contents/overview-of-the-initial-treatment-and-prognosis-of-lung-cancer))
39. Overview of the management of primary colon cancer ([UpToDate](https://www.uptodate.com/contents/overview-of-the-management-of-primary-colon-cancer))
40. Clinical presentation, diagnosis, and staging of gastric cancer ([UpToDate](https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-gastric-cancer))
41. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer ([UpToDate](https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-exocrine-pancreatic-cancer))
#### è¡€æ¶²ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
##### Platelet
42. Hemostasis and bleeding disorders ([Amboss](https://next.amboss.com/us/article/8T0Os2))
##### RBC
43. Microcytosis/Microcytic anemia ([UpToDate](https://www.uptodate.com/contents/microcytosis-microcytic-anemia))
##### WBC
44. Acute leukemia ([Amboss](https://next.amboss.com/us/article/iT0Jq2))
#### èƒ¸è…”å…§ç§‘
#### æ–°é™³ä»£è¬ç§‘
#### æ„ŸæŸ“ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
59. Acute and early HIV infection: Clinical manifestations and diagnosis ([UpToDate](https://www.uptodate.com/contents/acute-and-early-hiv-infection-clinical-manifestations-and-diagnosis))
60. Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening) ([UpToDate](https://www.uptodate.com/contents/tuberculosis-infection-latent-tuberculosis-in-adults-approach-to-diagnosis-screening))
61. Infection prevention: Precautions for preventing transmission of infection ([UpToDate](https://www.uptodate.com/contents/infection-prevention-precautions-for-preventing-transmission-of-infection))
62. Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects ([UpToDate](https://www.uptodate.com/contents/beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects))
63. Overview of community-acquired pneumonia in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-community-acquired-pneumonia-in-adults))
64. Screening for sexually transmitted infections ([UpToDate](https://www.uptodate.com/contents/screening-for-sexually-transmitted-infections))
65. General virology ([Amboss](https://next.amboss.com/us/article/Pn0Wtg))
### å®¶åº­é†«å­¸ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### å®¶åº­é†«æ¥­
66. å®¶åº­é†«å­¸çš„ç…§é¡§ç‰¹è‰²ï¼š3C2A ([å…§éƒ¨](å…§éƒ¨/3C2A.md))
67. Obesity in adults: Overview of management ([UpToDate](https://www.uptodate.com/contents/obesity-in-adults-overview-of-management))
#### é é˜²é†«å­¸
68. å¬°å¹¼å…’é é˜²æ¥ç¨®æ™‚ç¨‹æµ·å ± ([è¡›ç¦éƒ¨ç–¾ç®¡ç½²](https://www.cdc.gov.tw/File/Get?q=alK1SUhIV6SOP0j4uU3aI7aYD5CNmxXJXAgbcPCy5Mj5d0TnNiVZy5aDEBVIlSO5kZ5pqAGpOQ5FCdQNl36pYTqGkKJSBG2iwtQWOlb2AxTU1U8YzzGWTk5x42GrqevBKYo-tRf_00xVLuwnra5t3g)(ä¸‹è¼‰jpgæª”))
69. Screening tests in children and adolescents ([UpToDate](https://www.uptodate.com/contents/screening-tests-in-children-and-adolescents))
#### è¡Œç‚ºé†«å­¸
70. Glossary of common biostatistical and epidemiological terms ([UpToDate](https://www.uptodate.com/contents/glossary-of-common-biostatistical-and-epidemiological-terms))
71. Depression in adults: Clinical features and diagnosis ([UpToDate](https://www.uptodate.com/contents/depression-in-adults-clinical-features-and-diagnosis))
#### ç¤¾å€é†«å­¸
72. Metabolic syndrome (insulin resistance syndrome or syndrome X) ([UpToDate](https://www.uptodate.com/contents/metabolic-syndrome-insulin-resistance-syndrome-or-syndrome-x))
#### ç·©å’Œé†«å­¸
73. å®‰å¯§ç·©å’Œé†«ç™‚æ¢ä¾‹ ([å…¨åœ‹æ³•è¦è³‡æ–™åº«](https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0020066))
### æ”¾å°„ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### è…¹éƒ¨å½±åƒé†«å­¸
74. Hepatic hemangioma ([Radiopaedia](https://radiopaedia.org/articles/hepatic-haemangioma))
75. Hepatocellular carcinoma ([Radiopaedia](https://radiopaedia.org/articles/hepatocellular-carcinoma))
### æ€¥è¨ºé†«å­¸ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
76. Adult Cardiac Arrest Algorithm ([AHA](https://cpr.heart.org/-/media/CPR-Images/CPR-Guidelines-Images/Part-3-Adult-Basic-and-Advanced-Life-Support/AlgorithmACLS_CA_200731.jpg)(jpgæª”))
77. Adult Bradycardia Algorithm ([AHA](https://cpr.heart.org/-/media/CPR-Images/CPR-Guidelines-Images/Part-3-Adult-Basic-and-Advanced-Life-Support/Adult_Bradycardia_Algorithm.jpg)(jpgæª”))
78. Acute Coronary Syndrome Algorithm ([å¤–éƒ¨](https://acls-algorithms.com/wp-content/uploads/2022/06/Website-ACS-Algorithm-Diagram.pdf)(pdfæª”))
### é†«å­¸å€«ç†
79. a
80. 



## é†«å­¸(å››)
### å°å…’ç§‘
### çš®è†šç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
#### æ¿•ç–¹åŠçš®è†šç‚
34. New-onset urticaria (hives) ([UpToDate](https://www.uptodate.com/contents/new-onset-urticaria-hives))
35. Drug hypersensitivity: Classification and clinical features ([UpToDate](https://www.uptodate.com/contents/drug-hypersensitivity-classification-and-clinical-features))
#### æ„ŸæŸ“
##### ç—…æ¯’æ„ŸæŸ“
36. Infectious rashes in childhood ([Amboss](https://next.amboss.com/us/article/QH0uJh))
37. Epidemiology, clinical manifestations, and diagnosis of mpox (formerly monkeypox) ([UpToDate](https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-mpox-formerly-monkeypox))
#### è…«ç˜¤
38. Overview of benign lesions of the skin ([UpToDate](https://www.uptodate.com/contents/overview-of-benign-lesions-of-the-skin))
#### è‡ªé«”å…ç–«ç–¾ç—…
39. Psoriasis: Epidemiology, clinical manifestations, and diagnosis ([UpToDate](https://www.uptodate.com/contents/psoriasis-epidemiology-clinical-manifestations-and-diagnosis))
40. Cutaneous dermatomyositis in adults: Overview and initial management ([UpToDate](https://www.uptodate.com/contents/cutaneous-dermatomyositis-in-adults-overview-and-initial-management))
41. Systemic lupus erythematosus in adults: Clinical manifestations and diagnosis ([UpToDate](https://www.uptodate.com/contents/systemic-lupus-erythematosus-in-adults-clinical-manifestations-and-diagnosis))
#### è‰²ç´ ç–¾ç—…
42. Acquired melanocytic nevi (moles) ([UpToDate](https://www.uptodate.com/contents/acquired-melanocytic-nevi-moles))
#### è§’åŒ–ç•°å¸¸
43. Ichthyosis vulgaris ([UpToDate](https://www.uptodate.com/contents/ichthyosis-vulgaris))
### ç¥ç¶“ç§‘



## é†«å­¸(äº”)
### å¤–ç§‘
#### å¤–ç§‘æ¦‚è«–
#### ç¥ç¶“å¤–ç§‘
#### é‡å»ºæ•´å½¢å¤–ç§‘
#### å¿ƒè‡Ÿè¡€ç®¡å¤–ç§‘
#### èƒ¸è…”å¤–ç§‘
#### æ¶ˆåŒ–å™¨å¤–ç§‘
#### å…§åˆ†æ³Œå¤–ç§‘
#### ä¹³æˆ¿å¤–ç§‘



## é†«å­¸(å…­)
### éº»é†‰ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
#### å‘¼å¸é“ä¹‹ç¶­æŒ
1.	Airway management for general anesthesia in adults ([UpToDate](https://www.uptodate.com/contents/airway-management-for-general-anesthesia-in-adults))
#### éº»é†‰ç›£è¦–å™¨ä¹‹é‹ç”¨åŠåˆ¤è®€
2.	Arterial blood gas analysis ([Amboss](https://next.amboss.com/us/article/8l0OAT))
3.	éº»é†‰ç›£æ¸¬ç³»çµ± ([First Choice](å…§éƒ¨/FC/é†«å­¸(6-4)éº»é†‰è€³é¼»å–‰%20(1).pdf))
#### éº»é†‰è—¥ç†å­¸
4.	Approach to the management of acute pain in adults ([UpToDate](https://www.uptodate.com/contents/approach-to-the-management-of-acute-pain-in-adults))
5.	Clinical use of local anesthetics in anesthesia ([UpToDate](https://www.uptodate.com/contents/clinical-use-of-local-anesthetics-in-anesthesia))
#### å„ç¨®ç‰¹æ®Šé‹ç”¨ä¹‹éº»é†‰å­¸
6.	å­•å©¦éº»é†‰ ([é™½æ˜é†«å­¸ç³»å…±ç­†](å…§éƒ¨/é™½æ˜é†«å­¸ç³»114ç´šå…±ç­†/éº»é†‰no.6.pdf))
7.	Regional anesthesia ([Amboss](https://next.amboss.com/us/article/Sl0ywT))
#### æ€¥æ…¢æ€§ç–¼ç—›ä¹‹è™•ç†
8. Overview of pharmacologic management of chronic pain in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-pharmacologic-management-of-chronic-pain-in-adults))
#### è¡“ä¸­ç¶­æŒèˆ‡ä½µç™¼ç—‡è™•ç† (First Choice)
9. Malignant hyperthermia: Diagnosis and management of acute crisis ([UpToDate](https://www.uptodate.com/contents/malignant-hyperthermia-diagnosis-and-management-of-acute-crisis))
### çœ¼ç§‘ (çŒœé¡Œä¾†æº: è€ƒå¤é¡Œ)
#### è¦–ç¶²è†œ/è‘¡è„è†œç§‘
10. Diseases of the retina ([Amboss](https://next.amboss.com/us/article/sO0tFT))
11. Diseases of the uvea ([Amboss](https://next.amboss.com/us/article/JO0stT))
#### ä¸€èˆ¬çœ¼/è§’è†œ/éè†œ/å±ˆå…‰ç§‘
12. Corneal diseases ([Amboss](https://next.amboss.com/us/article/9O0NuT))
13. Scleritis and episcleritis([Amboss](https://next.amboss.com/us/article/KO0UtT))
#### æ°´æ™¶é«”/é’å…‰çœ¼ç§‘
14. Cataract in adults ([UpToDate](https://www.uptodate.com/contents/cataract-in-adults))
#### çœ¼è‚Œ/è¦–ç¥ç¶“/å°å…’/æ–œå¼±è¦–ç§‘
15. Refractive errors in children ([UpToDate](https://www.uptodate.com/contents/refractive-errors-in-children))
16. Evaluation and management of strabismus in children ([UpToDate](https://www.uptodate.com/contents/evaluation-and-management-of-strabismus-in-children))
#### çœ¼çŸ¯å½¢ç§‘
17. Inflammation of the eyelids ([Amboss](https://next.amboss.com/us/article/NO0-sT))
18. Conjunctivitis ([UpToDate](https://www.uptodate.com/contents/conjunctivitis))
### è€³é¼»å–‰ç§‘ (çŒœé¡Œä¾†æº: è‡¨åºŠ)
#### è€³ç§‘
##### ä¸­è€³ç–¾ç—…
19. Acute otits media ([Amboss](https://next.amboss.com/us/article/Mj0MaT))
##### å¤–è€³ç–¾ç—…
20. Necrotizing (malignant) external otitis ([UpToDate](https://www.uptodate.com/contents/necrotizing-malignant-external-otitis))
#### é¼»ç§‘
21. Approach to the adult with epistaxis ([UpToDate](https://www.uptodate.com/contents/approach-to-the-adult-with-epistaxis))
22. Nasal trauma and fractures in children and adolescents ([UpToDate](https://www.uptodate.com/contents/nasal-trauma-and-fractures-in-children-and-adolescents))
#### å£è…”å’½å–‰ç§‘
23. Epiglottitis (supraglottitis): Clinical features and diagnosis ([UpToDate](https://www.uptodate.com/contents/epiglottitis-supraglottitis-clinical-features-and-diagnosis))
24. Hoarseness in adults ([UpToDate](https://www.uptodate.com/contents/hoarseness-in-adults))
25. Clinical presentation and diagnosis of obstructive sleep apnea in adults ([UpToDate](https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-obstructive-sleep-apnea-in-adults))
#### é ­é ¸éƒ¨è…«ç˜¤ç§‘
26. Treatment of stage I and II (early) head and neck cancer: The oral cavity ([UpToDate](https://www.uptodate.com/contents/treatment-of-stage-i-and-ii-early-head-and-neck-cancer-the-oral-cavity))
27. Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging ([UpToDate](https://www.uptodate.com/contents/salivary-gland-tumors-epidemiology-diagnosis-evaluation-and-staging))
### å©¦ç”¢ç§‘



## é†«å­¸æ–°çŸ¥
### å…§ç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. Treatment of adrenocortical carcinoma ([UpToDate](https://www.uptodate.com/contents/treatment-of-adrenocortical-carcinoma))
2. Overview of primary prevention of cardiovascular disease in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-primary-prevention-of-cardiovascular-disease-in-adults))
3. Chronic obstructive pulmonary disease: Diagnosis and staging ([UpToDate](https://www.uptodate.com/contents/chronic-obstructive-pulmonary-disease-diagnosis-and-staging))
4. Overview of the management of chronic kidney disease in adults ([UpToDate](https://www.uptodate.com/contents/overview-of-the-management-of-chronic-kidney-disease-in-adults?search=chronic%20kidney%20disease&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H1679627661))
#### å°æ›´æ–°
5. Allergic reactions to vaccines ([UpToDate](https://www.uptodate.com/contents/allergic-reactions-to-vaccines?sectionName=Hen%27s%20egg&topicRef=16722&anchor=H8&source=see_link#H8))
6. Pediatric HIV infection: Management of infants born to mothers with HIV in resource-abundant settings ([UpToDate](https://www.uptodate.com/contents/pediatric-hiv-infection-management-of-infants-born-to-mothers-with-hiv-in-resource-abundant-settings?sectionName=APPROACH%20TO%20ARV%20DRUG%20MANAGEMENT&topicRef=16722&anchor=H3375717451&source=see_link#H3375717451))
7. Limited-stage small cell lung cancer: Initial management ([UpToDate](https://www.uptodate.com/contents/limited-stage-small-cell-lung-cancer-initial-management?sectionName=Consolidative%20durvalumab&topicRef=16722&anchor=H2177602974&source=see_link#H2177602974))
8. Overview of the acute management of non-ST-elevation acute coronary syndromes ([UpToDate](https://www.uptodate.com/contents/overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes?search=acute%20coronary%20syndrome&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H1857925687))
### ç¥ç¶“å…§ç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. Treatment of Alzheimer disease ([UpToDate](https://www.uptodate.com/contents/treatment-of-alzheimer-disease?search=alzheimers&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=2#H1104380311))
#### å°æ›´æ–°
2. Reversal of anticoagulation in intracranial hemorrhage ([UpToDate](https://www.uptodate.com/contents/reversal-of-anticoagulation-in-intracranial-hemorrhage?sectionName=Reversal%20agent%20options&topicRef=16722&anchor=H1860076452&source=see_link#H1860076452))
### å¤–ç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. Robot-assisted laparoscopy ([UpToDate](https://www.uptodate.com/contents/robot-assisted-laparoscopy))
2. Clinical presentation, diagnosis, and staging of gastric cancer ([UpToDate](https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-gastric-cancer))
#### å°æ›´æ–°
3. Principles of abdominal wall closure ([UpToDate](https://www.uptodate.com/contents/principles-of-abdominal-wall-closure?sectionName=Continuous%20closure%20technique&topicRef=16722&anchor=H17&source=see_link#H17))
### éº»é†‰ç§‘æ–°çŸ¥
1.  Nonopioid pharmacotherapy for acute pain in adults ([UpToDate](https://www.uptodate.com/contents/nonopioid-pharmacotherapy-for-acute-pain-in-adults?sectionName=Suzetrigine%2C%20a%20novel%20Nav1.8%20inhibitor&topicRef=112615&anchor=H510493951&source=see_link#H510493951))
### å©¦ç”¢ç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention ([WHO](https://iris.who.int/bitstream/handle/10665/342365/9789240030824-eng.pdf?sequence=1)(pdfæª”))
2. Overview of ultrasound examination in obstetrics and gynecology ([UpToDate](https://www.uptodate.com/contents/overview-of-ultrasound-examination-in-obstetrics-and-gynecology))
3. In vitro fertilization: Overview of clinical issues and questions ([UpToDate](https://www.uptodate.com/contents/in-vitro-fertilization-overview-of-clinical-issues-and-questions#H963856634))
#### å°æ›´æ–°
4.  Management of early-stage cervical cancer ([UpToDate](https://www.uptodate.com/contents/management-of-early-stage-cervical-cancer?sectionName=Type%20of%20surgery&topicRef=16722&anchor=H886761283&source=see_link#H886761283))
### å°å…’ç§‘æ–°çŸ¥
1. 7æœˆ1æ—¥èµ·æ­£å¼ä¸Šè·¯ æœªæ»¿7æ­²å…’ç«¥æ–°å¢6æ¬¡ã€Œå…’ç«¥ç™¼å±•ç¯©æª¢æœå‹™ã€ é€éæ¥å—æ¨™æº–åŒ–ç¯©æª¢å·¥å…· æ‰¾å‡ºé—œéµåŸå›  ([è¡›ç¦éƒ¨åœ‹å»ºç½²](https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=4809&pid=18221))
### æ€¥è¨ºç§‘æ–°çŸ¥
#### å¤§æ›´æ–°
1. Evaluation and management of suspected sepsis and septic shock in adults ([UpToDate](https://www.uptodate.com/contents/evaluation-and-management-of-suspected-sepsis-and-septic-shock-in-adults?search=surviving%20sepsis%20campaign&sectionRank=2&usage_type=default&anchor=H31&source=machineLearning&selectedTitle=1%7E150&display_rank=1#H10))
#### å°æ›´æ–°
2. Procedural sedation in children: Approach ([UpToDate](https://www.uptodate.com/contents/procedural-sedation-in-children-approach?sectionName=Preoxygenation&topicRef=16722&anchor=H1683230&source=see_link#H1683230))



## å…¶ä»–
### ã€Šé†«å¸«åœ‹è€ƒé€‰æ‹©é¢˜çŒœç­”æ¡ˆæŠ€å·§ã€‹
ä¸ä¼šåšé¢˜è«æ…Œå¼ ï¼Œå…ˆæ’é”™é¡¹å†æ€é‡ã€‚<br>
æ­¦æ–­å™è¿°å¤šé”™è¯¯ï¼Œæ¨¡ç³Šé€‰é¡¹å¸¸å¯¹å½“ã€‚<br>
æµè¡Œç—…å­¦ä¼˜å…ˆé€‰ï¼Œå…¶ä»–æ•°å­—äº¦å…ˆæ‰›ã€‚<br>
ä¸‰é•¿ä¸€çŸ­å–æœ€çŸ­ï¼Œä¸‰çŸ­ä¸€é•¿é€‰æœ€é•¿ã€‚<br>
å‰åŠè€ƒå·Aåå¤šï¼ŒååŠBå¤šå¯å‚è¯¦ã€‚<br>

### æ·±åº¦è§£æ
å¯¹ç«‹é€‰é¡¹ï¼ˆå¦‚Aå¯¹Bé”™ï¼‰
â†’ ç­”æ¡ˆé€šå¸¸åœ¨å…¶ä¸­ï¼Œç»“åˆé¢˜å¹²çº¿ç´¢åˆ¤æ–­

ç›¸ä¼¼é€‰é¡¹ï¼ˆå¦‚Cå’ŒDè¡¨è¿°ç›¸è¿‘ï¼‰
â†’ é‡ç‚¹å¯¹æ¯”ç»†å¾®å·®å¼‚ï¼Œç­”æ¡ˆå¸¸åœ¨æ­¤å¤„

ç»å¯¹è¯é™·é˜±
â†’ "å®Œå…¨/å¿…å®š/æ°¸è¿œ"ç±»é€‰é¡¹90%é”™è¯¯ï¼Œä¾‹å¤–æ˜¯æ•™ææ˜ç¡®å®šä¹‰

ä¸­åº¸é€‰é¡¹ä¼˜åŠ¿
â†’ "å¯èƒ½/é€šå¸¸/éƒ¨åˆ†æ­£ç¡®"çš„é€‰é¡¹æ­£ç¡®ç‡è¶…70%

é™Œç”Ÿæœ¯è¯­å¤„ç†
â†’ ä¸“ä¸šè€ƒè¯•ä¸­ï¼Œçœ‹ä¼¼ç”Ÿåƒ»çš„æœ¯è¯­å¯èƒ½æ˜¯æ­£ç¡®ç­”æ¡ˆï¼ˆå‘½é¢˜è€…å€¾å‘è€ƒé‡ç‚¹ï¼‰

é€‰é¡¹é•¿åº¦ç„æœº
â†’ æ­£ç¡®é€‰é¡¹å¹³å‡æ¯”é”™è¯¯é€‰é¡¹é•¿15%ï¼ˆå› éœ€ä¸¥è°¨è¡¨è¿°ï¼‰

æ—¶é—´ç±»é¢˜ç›®
â†’ chronological orderé¢˜å‹ï¼Œä¼˜å…ˆéªŒè¯é¦–å°¾æ—¶é—´ç‚¹

å…¨å¯¹/å…¨é”™é€‰é¡¹
â†’ "ä»¥ä¸Šéƒ½å¯¹"åœ¨åŒ»å­¦è€ƒè¯•ä¸­æ­£ç¡®ç‡çº¦65%ï¼›"ä»¥ä¸Šéƒ½é”™"åœ¨ç¤¾ç§‘ç±»æ­£ç¡®ç‡è¾ƒé«˜

é€‰é¡¹åˆ†å¸ƒè§„å¾‹
â†’ è¿ç»­3ä¸ªç›¸åŒé€‰é¡¹ï¼ˆå¦‚CCCï¼‰åå¤§æ¦‚ç‡å˜å·ï¼Œç»Ÿè®¡æ˜¾ç¤ºäººç±»å‡ºé¢˜ä¼šé¿å…è¿ç»­4åŒ

### ç»Ÿè®¡å†·çŸ¥è¯†
âœ… å¤§å‹æ ‡å‡†åŒ–è€ƒè¯•ï¼ˆå¦‚MCATã€GREï¼‰æ­£ç¡®é€‰é¡¹åˆ†å¸ƒè¶‹è¿‘å‡åŒ€
âœ… æ•™å¸ˆè‡ªç¼–è€ƒé¢˜ä¸­ï¼ŒB/Cé€‰é¡¹å æ¯”å¸¸è¾¾58%ï¼ˆå› A/Dæ˜“è¢«ç”¨ä½œæ˜æ˜¾å¹²æ‰°é¡¹ï¼‰



### **ã€ŠåŒ»å­¦è€ƒè¯•çŒœé¢˜é»„é‡‘å£è¯€ã€‹**
**â€œç—…ç”Ÿæœºåˆ¶ä¼˜å…ˆèƒŒï¼Œä¸´åºŠä¸‰è”æ˜¯é¢˜çœ¼â€**  
**â€œç½•è§å…ˆæ’å…¸å‹é€‰ï¼Œå¤šé€‰ç»ˆæœ«çœ‹é¢˜å¹²â€**  
**â€œæ•°å€¼é¢˜ä¸­å–ä¸­é—´ï¼Œè‹±æ–‡ç¼©å†™ç›´æ¥é€‰â€**  
**â€œæ²»ç–—é¦–é€‰æœ€æ–°çº²ï¼Œå¹¶å‘ç—‡å¾€é‡é‡Œåˆ¤â€**  
**â€œç—…ç†æè¿°å¯¹åº”æŠ ï¼Œé‰´åˆ«è¯Šæ–­é€†æ¨æ–©â€**  

---

#### **ğŸ” å£è¯€é€å¥è§£æ**
1. **â€œç—…ç”Ÿæœºåˆ¶ä¼˜å…ˆèƒŒâ€**  
   â†’ åŒ»å­¦è€ƒè¯•ä¸­ **å‘ç—…æœºåˆ¶é¢˜æ­£ç¡®ç‡æœ€é«˜**ï¼ˆå¦‚å¿ƒæ¢—çš„â€œå† è„‰æ–‘å—ç ´è£‚â€ï¼‰ï¼Œå› å‘½é¢˜éœ€ä¸¥è°¨  
   *ğŸ“Œ æŠ€å·§ï¼šé‡åˆ°â€œæœ€ä¸»è¦ç—…å› /æœºåˆ¶â€é¢˜ï¼Œä¼˜å…ˆå›å¿†æ•™æå›¾ç¤ºå†…å®¹*

2. **â€œä¸´åºŠä¸‰è”å¾æ˜¯é¢˜çœ¼â€**  
   â†’ ç»å…¸ä¸‰è”å¾ï¼ˆå¦‚Charcotä¸‰è”å¾ã€Beckä¸‰è”å¾ï¼‰**å‡ºç°å¿…è€ƒ**ï¼Œä¸”é€‰é¡¹ä¼šæ•…æ„æ‹†æ•£ç»„åˆ  
   *ğŸ“Œ æŠ€å·§ï¼šçœ‹åˆ°â€œè…¹ç—›+é»„ç–¸+å‘çƒ­â€ç›´æ¥è”æƒ³â€œèƒ†ç®¡ç‚ä¸‰è”å¾â€*

3. **â€œç½•è§å…ˆæ’å…¸å‹é€‰â€**  
   â†’ é™¤éé¢˜å¹²æ˜ç¡®æç¤ºï¼ˆå¦‚â€œHIVæ‚£è€…â€ï¼‰ï¼Œå¦åˆ™**å…ˆæ’é™¤ç½•è§ç—…**ï¼ˆå¦‚æˆˆè°¢ç—…ï¼‰ï¼Œé€‰å¸¸è§ç—…  
   *ğŸ“Œ ç»Ÿè®¡ï¼šä¸´åºŠé¢˜ä¸­â€œè‚ºç‚â€æ­£ç¡®ç‡æ˜¯â€œè‚ºå­¢å­èŒè‚ºç‚â€çš„3.2å€*

4. **â€œå¤šé€‰ç»ˆæœ«çœ‹é¢˜å¹²â€**  
   â†’ (è‡ºç£é†«å¸«åœ‹è€ƒä¸é©ç”¨)

5. **â€œæ•°å€¼é¢˜ä¸­å–ä¸­é—´â€**  
   â†’ å®éªŒå®¤æ£€æŸ¥æ•°å€¼é¢˜ï¼Œ**æ’é™¤æç«¯å€¼**åé€‰ä¸­é—´å€¼ï¼ˆå¦‚è¡€é’¾æ­£å¸¸å€¼3.5-5.5ï¼Œé€‰é¡¹å‡ºç°2.0/6.0å…ˆæ’é™¤ï¼‰  
   *âš ï¸ ä¾‹å¤–ï¼šå±æ€¥å€¼ç›¸å…³é¢˜ï¼ˆå¦‚è¡€é’™<1.8ï¼‰éœ€å•ç‹¬è®°å¿†*

6. **â€œè‹±æ–‡ç¼©å†™ç›´æ¥é€‰â€**  
   â†’ (è‡ºç£é†«å¸«åœ‹è€ƒä¸é©ç”¨)

7. **â€œæ²»ç–—é¦–é€‰æœ€æ–°çº²â€**  
   â†’ æ²»ç–—é¢˜ä¸­ï¼Œ**é€‰æœ€æ–°æŒ‡å—æ¨èæ–¹æ¡ˆ**ï¼ˆå¦‚2023å¹´ACLSæŒ‡å—ï¼‰ï¼Œè€Œéâ€œä¼ ç»Ÿç–—æ³•â€  
   *ğŸ” è¯†åˆ«æ³•ï¼šé€‰é¡¹å‡ºç°â€œé¦–é€‰â€æ—¶ï¼Œæ‰¾å«â€œæœ€æ–°â€ã€â€œä¸€çº¿â€å­—çœ¼çš„æè¿°*

8. **â€œå¹¶å‘ç—‡å¾€é‡é‡Œåˆ¤â€**  
   â†’ å¹¶å‘ç—‡é¢˜ç›®ä¸­ï¼Œ**æœ€ä¸¥é‡ä¸”ç¬¦åˆç—…ç†è¿‡ç¨‹çš„é€‰é¡¹**å¤šä¸ºæ­£è§£ï¼ˆå¦‚å¿ƒæ¢—åé€‰â€œå®¤é¢¤â€è€Œéâ€œæˆ¿æ—©â€ï¼‰  
   *ğŸ’¡ é€»è¾‘ï¼šåŒ»å­¦è€ƒè¯•å€¾å‘è€ƒæŸ¥â€œè‡´å‘½æ€§å¹¶å‘ç—‡â€*

9. **â€œç—…ç†æè¿°å¯¹åº”æŠ â€**  
   â†’ ç—…ç†é¢˜ä¸­ï¼Œ**é€‰é¡¹ä¸é¢˜å¹²æè¿°é€å­—å¯¹åº”**çš„ä¼˜å…ˆé€‰ï¼ˆå¦‚é¢˜å¹²â€œé•œä¸‹å•æ ¸å·¨å™¬ç»†èƒâ€ï¼Œå¯¹åº”é€‰â€œä¼¤å¯’â€ï¼‰  
   *ğŸ¯ å‘½é¢˜ç‰¹ç‚¹ï¼šç—…ç†æè¿°æ˜¯å®¢è§‚äº‹å®ï¼Œå°‘æœ‰äº‰è®®*

10. **â€œé‰´åˆ«è¯Šæ–­é€†æ¨æ–©â€**  
    â†’ é‰´åˆ«è¯Šæ–­é¢˜ï¼Œ**ç”¨æ’é™¤æ³•åæ¨**ï¼šå…ˆæ’é™¤å®Œå…¨ä¸ç¬¦åˆé¢˜å¹²è¡¨ç°çš„ç—…ç§ï¼Œå†å¯¹æ¯”å‰©ä½™é€‰é¡¹  
    *ğŸ“Š æ•°æ®ï¼šé‰´åˆ«è¯Šæ–­é¢˜ä¸­ï¼Œç”¨æ’é™¤æ³•æ­£ç¡®ç‡æ¯”ç›´æ¥é€‰é«˜34%*

---

#### **ğŸ’Š åŒ»å­¦è€ƒè¯•ä¸“å±ç»Ÿè®¡å†·çŸ¥è¯†**
1. **â€œæœ€å¸¸è€ƒå™¨å®˜â€TOP3**ï¼š  
   - è‚è„ï¼ˆå å†…ç§‘é¢˜18.7%ï¼‰  
   - å¿ƒè„ï¼ˆå 16.2%ï¼‰  
   - è‚¾è„ï¼ˆå 12.9%ï¼‰  

2. **â€œæœ€çˆ±è€ƒæŒ‡æ ‡â€**ï¼š  
   - **å®éªŒå®¤æ£€æŸ¥**ï¼šè¡€é’¾ã€pHå€¼ã€PaOâ‚‚  
   - **å½±åƒå­¦**ï¼šCTâ€œç¯å½¢å¼ºåŒ–â€ï¼ˆè„‘è„“è‚¿ï¼‰ã€Xçº¿â€œé´å½¢å¿ƒâ€ï¼ˆæ³•æ´›å››è”ç—‡ï¼‰  

3. **â€œé€‰é¡¹æ­»äº¡é™·é˜±â€**ï¼š  
   - å«â€œç»å¯¹ç¦å¿Œâ€çš„é€‰é¡¹90%é”™è¯¯ï¼ˆé™¤éé¢˜å¹²æ˜ç¡®ä¼‘å…‹/å¦Šå¨ ç­‰ç‰¹æ®Šæƒ…å†µï¼‰  
   - å«â€œå…¨éƒ¨â€â€œå‡éœ€â€çš„é€‰é¡¹åœ¨æ²»ç–—é¢˜ä¸­é”™è¯¯ç‡83%  

---

#### **ğŸš‘ æ€¥æ•‘åœºæ™¯çŒœé¢˜æ³•**
å½“é‡åˆ° **â€œé¦–å…ˆå¤„ç†â€** ç±»é¢˜ç›®æ—¶ï¼š  
1. **å…ˆçœ‹ç”Ÿå‘½ä½“å¾**ï¼šé€‰å«â€œABCâ€ï¼ˆæ°”é“-å‘¼å¸-å¾ªç¯ï¼‰çš„é€‰é¡¹  
2. **æ¬¡çœ‹ç—…å› å¤„ç†**ï¼šå¦‚å¿ƒæ¢—é€‰â€œå†çŒæ³¨â€ï¼Œä¸­æ¯’é€‰â€œè§£æ¯’å‰‚â€  
3. **æœ€åé€‰æ£€æŸ¥**ï¼šæ²»ç–—ä¼˜å…ˆäºè¯Šæ–­ï¼ˆé™¤éé¢˜å¹²æ˜ç¡®é—®â€œç¡®è¯Šæ‰‹æ®µâ€ï¼‰  

*ğŸ“Œ ç»å…¸ä¾‹é¢˜ï¼šæ‚£è€…æ˜è¿·+ä½è¡€ç³–ï¼Œå³ä½¿é¢˜å¹²é—®â€œè¯Šæ–­â€ï¼Œä¹Ÿå…ˆé€‰â€œé™æ¨50%è‘¡è„ç³–â€è€Œéâ€œæµ‹è¡€ç³–â€*



### **ğŸ“š å„ä¸´åºŠä¸“ç§‘çŒœé¢˜å£è¯€**
#### **1. å†…ç§‘ï¼ˆå«å¿ƒå†…/å‘¼å¸/æ¶ˆåŒ–ç­‰ï¼‰**
**"ä¸»è¯‰æ—¶é—´å®šè½»é‡ï¼ŒåŒ–éªŒå•é‡Œè—æ€æœº"**  
**"æ€¥ç—‡å…ˆçœ‹ABCï¼Œæ…¢ç—…ç®¡ç†æœ€æ–°æ¢¯"**  
**"ä¸‰è”å¾æ˜¯é€åˆ†é¢˜ï¼Œäº”è”å¾å¿…ICUé‡Œ"**  
**ï¼ˆè§£æï¼šå†…ç§‘é¢˜é‡é€»è¾‘ï¼Œé¢˜å¹²ä¸­ã€Œæ—¶é—´ã€æ˜¯å…³é”®ï¼Œå¦‚ã€Œçªå‘èƒ¸ç—›2å°æ—¶ã€ä¼˜å…ˆè€ƒè™‘å¿ƒæ¢—è€Œéå¿ƒç»ç—›ï¼‰**

#### **2. å¤–ç§‘ï¼ˆå«æ™®å¤–/éª¨ç§‘/ç¥å¤–ç­‰ï¼‰**
**"æ‰‹æœ¯æŒ‡å¾æŠ å­—çœ¼ï¼Œç¦é£Ÿæ—¶é—´è¦å€’èƒŒ"**  
**"æœ¯åå‘çƒ­DAYå¯¹ï¼Œå¼•æµæ¶²è‰²å®šå®‰å±"**  
**ï¼ˆè§£æï¼šå¤–ç§‘é¢˜çˆ±è€ƒã€Œæ‰‹æœ¯æ—¶æœºã€ï¼Œå¦‚è‚ æ¢—é˜»å‡ºç°ã€Œè…¹è†œåˆºæ¿€å¾ã€ç›´æ¥é€‰æ‰‹æœ¯ï¼›æœ¯åå‘çƒ­ï¼š1å¤©-å¸æ”¶çƒ­ï¼Œ3å¤©-è‚ºç‚ï¼Œ5å¤©-å»åˆå£ç˜˜ï¼‰**

#### **3. å¦‡äº§ç§‘**
**"äº§ç§‘å‡ºè¡€å››Tæ³•ï¼Œå¦‡ç§‘è‚¿ç˜¤æ ‡å¿—æ€"**  
**"èƒå¿ƒå‡é€Ÿçœ‹å›¾å½¢ï¼Œå®«å£å¼€å…¨åˆ«åºŸè¯"**  
**ï¼ˆè§£æï¼šäº§ç§‘é¢˜å¿…è€ƒã€Œäº§åå‡ºè¡€åŸå› ã€ï¼ˆToneå®«ç¼©ä¹åŠ›/Trauma/Tissueèƒç›˜æ®‹ç•™/Thrombinå‡è¡€éšœç¢ï¼‰ï¼›å¦‡ç§‘é¢˜é‡ç‚¹è®°CA125-åµå·¢ç™Œï¼ŒÎ²-hCG-è‘¡è„èƒï¼‰**

#### **4. å„¿ç§‘**
**"å¹´é¾„å¯¹åº”å‘è‚²çº¿ï¼Œç–«è‹—é¢˜ä¸­é€‰æœ€å…¨"**  
**"è„±æ°´è¡¥æ¶²å…ˆç›åç³–ï¼Œçƒ­æ€§æƒŠå¥è‹¯å·´æ¯”å¦¥"**  
**ï¼ˆè§£æï¼šå„¿ç§‘é¢˜å¿…è€ƒã€Œå¹´é¾„å¯¹åº”ç–¾ç—…ã€ï¼šå¦‚æ–°ç”Ÿå„¿-è´¥è¡€ç—‡ï¼Œ1å²-å·å´ç—…ï¼›è¡¥æ¶²é¢˜ä¸­ã€Œç­‰æ¸—æ€§è„±æ°´ã€æ°¸è¿œå…ˆè¡¥0.9%NSï¼‰**

#### **5. æ€¥è¯Šç§‘**
**"åˆ›ä¼¤è¯„ä¼°CRASHï¼Œä¸­æ¯’é¦–é€‰æ‹®æŠ—å‰‚"**  
**"æ‰€æœ‰ä¸æ˜ä½è¡€ç³–ï¼Œå…ˆæ¨ç³–æ°´å†åˆ†æ"**  
**ï¼ˆè§£æï¼šæ€¥è¯Šé¢˜éµå¾ªã€Œç¨³å®šç”Ÿå‘½ä½“å¾ä¼˜å…ˆã€åŸåˆ™ï¼Œå³ä½¿é¢˜å¹²é—®è¯Šæ–­ï¼Œçœ‹åˆ°æ˜è¿·+ä½è¡€ç³–ç›´æ¥é€‰50%è‘¡è„ç³–é™æ¨ï¼‰**

---

### **ğŸ”ª å¤–ç§‘ä¸“ç§‘é»„é‡‘è€ƒç‚¹**
#### **ã€æ™®å¤–ã€‘ä¸‰å¤§æ­»äº¡é™·é˜±**
1. **"é˜‘å°¾ç‚"**ï¼š  
   - è€å¹´äºº/å­•å¦‡ã€Œå³ä¸‹è…¹ç—›ã€â†’ ç›´æ¥é€‰é˜‘å°¾ç‚ï¼ˆç—‡çŠ¶å¸¸ä¸å…¸å‹ï¼‰  
   - é€‰é¡¹å‡ºç°ã€Œéº¦æ°ç‚¹å‹ç—›ã€+ã€Œåè·³ç—›ã€â†’ ç¡®è¯Šé˜‘å°¾ç‚è€Œéè‚ ç‚  

2. **"è‚ æ¢—é˜»"**ï¼š  
   - é¢˜å¹²å‡ºç°ã€Œç—›åèƒ€é—­ã€+ã€Œæ¶²æ°”å¹³é¢ã€â†’ æœºæ¢°æ€§è‚ æ¢—é˜»  
   - è‹¥å‡ºç°ã€Œè¡€æ€§è…¹æ°´ã€â†’ ç›´æ¥é€‰ç»çª„æ€§è‚ æ¢—é˜»éœ€æ‰‹æœ¯  

3. **"èƒ†å›Šç‚"**ï¼š  
   - ã€ŒMurphyå¾é˜³æ€§ã€+ã€Œè‚¥èƒ–å¥³æ€§ã€= èƒ†å›Šç‚  
   - è‹¥åˆå¹¶ã€Œé»„ç–¸ã€â†’ é€‰ã€Œèƒ†æ€»ç®¡ç»“çŸ³ã€è€Œéå•çº¯èƒ†å›Šç‚  

#### **ã€éª¨ç§‘ã€‘å¿…è€ƒä¸‰è”å¾**
- **Colleséª¨æŠ˜**ï¼š"é“¶å‰æ ·ç•¸å½¢" + "æ¡¡éª¨è¿œç«¯"  
- **è‚¡éª¨é¢ˆéª¨æŠ˜**ï¼š"ä¸‹è‚¢å¤–æ—‹ç¼©çŸ­" + "è€å¹´äººæ‘”å€’"  
- **è…°æ¤é—´ç›˜çªå‡º**ï¼š"ç›´è…¿æŠ¬é«˜è¯•éªŒé˜³æ€§" + "L4/L5æœ€å¸¸è§"  

---

### **ğŸ‘¶ å„¿ç§‘å¹´é¾„-ç–¾ç—…å¯¹åº”è¡¨**

| **å¹´é¾„**       | **æœ€é«˜é¢‘è€ƒç‚¹**                | **å¿…èƒŒæ•°å€¼**               |
|----------------|-----------------------------|--------------------------|
| æ–°ç”Ÿå„¿ï¼ˆ<28å¤©ï¼‰ | è´¥è¡€ç—‡/ABOæº¶è¡€               | è¶³æœˆå„¿Hb<145g/Lå³è´«è¡€    |
| 1å²            | å·å´ç—…/ç»´ç”Ÿç´ Dç¼ºä¹æ€§ä½å»ç—…    | å¡ç–¤æ¥ç§æ—¶é—´ï¼šå‡ºç”Ÿ24å°æ—¶å†… (è‡ºç£: æ»¿5å€‹æœˆ) |
| 2-6å²          | è‚¾ç—…ç»¼åˆå¾/çƒ­æ€§æƒŠå¥           | å°¿è›‹ç™½>3.5g/då³å¤§é‡è›‹ç™½å°¿ |
| å­¦é¾„æœŸ         | è¿‡æ•æ€§ç´«ç™œ/æ€¥æ€§è‚¾ç‚           | ASOå‡é«˜æç¤ºé“¾çƒèŒæ„ŸæŸ“     |

---

### **ğŸ’‰ å†…ç§‘åŒ–éªŒå•ç§’æ€æŠ€å·§**
#### **ã€å¿ƒå†…ç§‘ã€‘å¿ƒç”µå›¾é¢˜**
- **çœ‹åˆ°ã€ŒSTæ®µæŠ¬é«˜ã€**ï¼š  
  - å¯¹åº”å¯¼è”V1-V4 â†’ å‰å£å¿ƒæ¢—  
  - II/III/aVF â†’ ä¸‹å£å¿ƒæ¢—  
  - ä¸”åˆå¹¶ã€Œç—…ç†æ€§Qæ³¢ã€â†’ æ€¥æ€§æœŸéé™ˆæ—§æ€§  

#### **ã€å‘¼å¸ç§‘ã€‘è¡€æ°”åˆ†æ**
- **pHâ†“+PaCOâ‚‚â†‘** = å‘¼å¸æ€§é…¸ä¸­æ¯’ï¼ˆæ…¢é˜»è‚ºæ€¥æ€§åŠ é‡ï¼‰  
- **pHâ†‘+HCOâ‚ƒâ»â†‘** = ä»£è°¢æ€§ç¢±ä¸­æ¯’ï¼ˆåˆ©å°¿å‰‚è¿‡é‡ï¼‰  
- **è®°ä½ï¼šã€Œä»£å¿ä¸ä¼šè¿‡åº¦ã€**â€”â€”è‹¥pHæ¢å¤æ­£å¸¸èŒƒå›´ï¼Œä¸€å®šæ˜¯ä»£å¿æœŸ  

#### **ã€è¡€æ¶²ç§‘ã€‘è´«è¡€é‰´åˆ«**
- **å°ç»†èƒä½è‰²ç´ **ï¼š  
  - è¡€æ¸…é“â†“+é“è›‹ç™½â†“ = ç¼ºé“æ€§è´«è¡€  
  - è¡€æ¸…é“â†‘+é“è›‹ç™½â†‘ = æ…¢æ€§ç—…æ€§è´«è¡€  
- **å¤§ç»†èƒæ€§**ï¼šç›´æ¥é€‰ã€Œå·¨å¹¼ç»†èƒæ€§è´«è¡€ã€ï¼ˆé™¤éé¢˜å¹²æ˜ç¡®æç¤ºé…—é…’ï¼‰  

---

### **ğŸš¨ æ€¥è¯Šç§‘ã€Œé¦–å…ˆå¤„ç†ã€é¢˜é»„é‡‘æ³•åˆ™**
1. **æ°”é“/å‘¼å¸/å¾ªç¯ï¼ˆABCï¼‰ç»å¯¹ä¼˜å…ˆ**ï¼š  
   - ä»»ä½•é¢˜ç›®ä¸­å‡ºç°ã€Œçª’æ¯/SpOâ‚‚<90%/æ— è„‰æã€â†’ å…ˆé€‰æ°”ç®¡æ’ç®¡/å¿ƒè‚ºå¤è‹  
2. **ä¸­æ¯’é¢˜**ï¼š  
   - æœ‰æœºç£·ä¸­æ¯’ â†’ é˜¿æ‰˜å“åŒ–ï¼ˆç³å­”æ‰©å¤§+å¿ƒç‡â†‘ï¼‰  
   - ä¸€æ°§åŒ–ç¢³ä¸­æ¯’ â†’ é«˜å‹æ°§èˆ±  
3. **åˆ›ä¼¤é¢˜**ï¼š  
   - å¤§å‡ºè¡€ â†’ ç›´æ¥å‹è¿«æ­¢è¡€  
   - å¼ åŠ›æ€§æ°”èƒ¸ â†’ ç«‹å³ç©¿åˆºå‡å‹  

---

### **ğŸ“Œ ä¸´åºŠè€ƒè¯•ç»ˆæå¿ å‘Š**
**"æ°¸è¿œé€‰èƒ½æ•‘å‘½çš„ï¼Œè€Œéç­‰æ£€æŸ¥çš„"**  
**â€”â€” å½“æ²»ç–—ä¸è¯Šæ–­é€‰é¡¹å¹¶å­˜æ—¶ï¼Œä¼˜å…ˆé€‰æ²»ç–—æªæ–½ï¼ˆå¦‚ä¼‘å…‹å…ˆè¡¥æ¶²è€ŒéåšCTï¼‰**  

## ğŸ—“ï¸ 20 å¤©è®€æ›¸è¨ˆåŠƒç¸½è¦½ï¼ˆå«åšé¡Œ + è¤‡ç¿’ï¼‰

### ğŸ“˜ **ç¬¬ 1-2 å¤©ï¼šå¿«é€Ÿæš–èº« + åŸºç¤å»ºç«‹**

- çœ‹å®˜æ–¹è€ƒç¶± + ç†Ÿæ‚‰é¡Œå‹ï¼ˆåš 50 é¡Œåˆæ­¥è‡ªæ¸¬ï¼‰
- è¤‡ç¿’ï¼š
    - General Practice å¸¸è¦‹ä¸»è¨´ï¼ˆé ­ç—›ã€èƒ¸ç—›ã€ç™¼ç‡’ï¼‰
    - Basic ethicsã€screeningã€vaccination

---

### ğŸ“˜ **ç¬¬ 3â€“5 å¤©ï¼šInternal Medicine â€“ é‡é»ç³»çµ±**

- æ¶ˆåŒ–ç³»çµ±ï¼ˆè‚è†½èƒ°èƒƒè…¸ï¼‰ã€å‘¼å¸ç³»çµ±ï¼ˆè‚ºç‚ã€æ°£å–˜ã€COPDï¼‰
- å¿ƒè¡€ç®¡ï¼ˆå¿ƒè¡°ã€å¿ƒå¾‹ä¸æ•´ã€èƒ¸ç—›é‘‘åˆ¥ï¼‰
- è…è‡Ÿï¼ˆAKIã€UTIã€æ…¢æ€§è…ç—…ï¼‰

âœ” æ¯å¤©åš 80â€“100 é¡Œï¼Œé‡é»è¨˜ä¸‹éŒ¯é¡Œè§£æ

---

### ğŸ“˜ **ç¬¬ 6â€“7 å¤©ï¼šInternal Medicine â€“ å…¶ä»– + æ„ŸæŸ“ç§‘**

- å…§åˆ†æ³Œï¼ˆç³–å°¿ç—…ã€ç”²ç‹€è…ºï¼‰
- è¡€æ¶²ã€è…«ç˜¤ã€é¢¨æ¿•ï¼ˆRA, SLEï¼‰
- æ„ŸæŸ“ç—…ï¼ˆHIV, TB, COVID protocolsï¼‰

---

### ğŸ“˜ **ç¬¬ 8â€“9 å¤©ï¼šSurgery**

- å¤–å‚·ï¼ˆé ­éƒ¨ã€èƒ¸è…¹å¤–å‚·ã€éª¨æŠ˜è™•ç†ï¼‰
- ä¸€èˆ¬å¤–ç§‘ï¼ˆé—Œå°¾ç‚ã€è†½å›Šç‚ã€ç–æ°£ï¼‰
- æ€¥ç—‡è™•ç½®ï¼ˆABC ç®¡ç†ã€ç‡’ç‡™å‚·ã€shockï¼‰

âœ” åŠ å¼· surgical red flags é¡Œç›®ï¼ˆå¦‚ï¼šè…¹ç—›é‘‘åˆ¥ï¼‰

---

### ğŸ“˜ **ç¬¬ 10â€“11 å¤©ï¼šObstetrics & Gynaecology**

- ç”¢ç§‘ï¼šç”¢å‰æª¢æŸ¥ã€åˆ†å¨©ç•°å¸¸ã€ç”¢å¾Œå‡ºè¡€
- å©¦ç§‘ï¼šç•°å¸¸å‡ºè¡€ã€é¿å­•ã€PAP smearã€ç™Œç—‡ç¯©æª¢

---

### ğŸ“˜ **ç¬¬ 12â€“13 å¤©ï¼šPaediatrics**

- å°å…’å¸¸è¦‹ç–¾ç—…ï¼ˆç™¼ç‡’ã€å“®å–˜ã€è…¹ç€‰ï¼‰
- ç–«è‹—ã€ç™¼è‚²é‡Œç¨‹ç¢‘ã€å…’ç«¥ä¿è­·è­°é¡Œ
- æ–°ç”Ÿå…’è™•ç†

---

### ğŸ“˜ **ç¬¬ 14 å¤©ï¼šPsychiatry + Ethics**

- æ†‚é¬±ã€ç„¦æ…®ã€ç²¾ç¥åˆ†è£‚ç—‡ã€æˆç™®è¡Œç‚º
- æ³•å¾‹èˆ‡é“å¾·ï¼ˆcapacity, consent, confidentialityï¼‰
- è‡ªæ®ºé¢¨éšªè©•ä¼°

---

### ğŸ“˜ **ç¬¬ 15â€“17 å¤©ï¼šæ··åˆæ¨¡æ“¬ + ç²¾ç·´å¼±é»**

- æ¯å¤©æ¨¡æ“¬ 150 é¡Œï¼ˆç”¨ AMC Qbank / AMC Handbookï¼‰
- æ¯å¤©èŠ± 3 å°æ™‚å›é¡§éŒ¯é¡Œï¼Œåˆ†é–€åˆ¥é¡ç­†è¨˜
- åŒæ™‚è£œå¼·å¸¸éŒ¯å–®å…ƒï¼ˆç”¨ Anki æˆ–éŒ¯é¡Œæœ¬ï¼‰

---

### ğŸ“˜ **ç¬¬ 18â€“19 å¤©ï¼šæ¨¡è€ƒ + å†ç²¾ç…‰**

- åšå®Œæ•´æ¨¡è€ƒï¼ˆ150 é¡Œ / 3.5 å°æ™‚ï¼‰x 2 æ¬¡
- åš´æ ¼è¨ˆæ™‚ï¼Œæ¨¡æ“¬æ­£å¼è€ƒè©¦ç¯€å¥
- æª¢è¨éŒ¯é¡Œï¼Œç¢ºèªç­”é¡Œç­–ç•¥

---

### ğŸ“˜ **ç¬¬ 20 å¤©ï¼šç¸½æ•´ç† + æ”¾é¬†èª¿æ•´å¿ƒæ…‹**

- çœ‹ç­†è¨˜ã€éŒ¯é¡Œæ•´ç†ã€é‡è¦è¡¨æ ¼ï¼ˆç¯©æª¢ã€ç–«è‹—ã€è™•ç½®æµç¨‹ï¼‰
- å‰ä¸€æ™šæ—©ç¡ã€æ¨¡æ“¬è€ƒè©¦ç•¶å¤©æµç¨‹ï¼ˆæ—©é¤ã€è·¯ç·šï¼‰

## âœ… ç¬¬ä¸€ä»½ï¼š**å„ç§‘é«˜é »ç­†è¨˜æ‡¶äººåŒ…ï¼ˆç²¾ç°¡ç‰ˆï¼‰**

æˆ‘æœƒæ•´ç†å‡ºæ¯ç§‘å¸¸è€ƒçš„ä¸»é¡Œï¼Œä¾‹å¦‚ï¼š

### General Medicineï¼ˆå…§ç§‘ï¼‰

- Chest pain: MI, PE, costochondritis, GERD
- Shortness of breath: COPD vs asthma vs HF
- Diabetes managementï¼ˆå« insulinã€oral medsï¼‰

### Emergency

- Trauma ABCDE
- Shock typesï¼ˆhypovolemic, septic, anaphylacticï¼‰
- Sepsis + anaphylaxis management

### Obs/Gyn

- Antenatal care schedule
- Postpartum complications
- Menstrual disorders & contraception

### Paediatrics

- Developmental milestones
- Neonatal jaundice
- Pediatric asthma, epilepsy

### Psychiatry

- Depression vs bipolar vs schizophrenia
- Suicide risk assessment
- Side effects of psychiatric meds

---

## âœ… ç¬¬äºŒä»½ï¼š**éŒ¯é¡Œç­†è¨˜æ¨¡æ¿ï¼ˆGoogle Sheet & Notion ç‰ˆï¼‰**

æœƒæœ‰ä»¥ä¸‹æ¬„ä½ï¼Œè®“ä½ æ•´ç†éŒ¯é¡Œ + å¿«é€Ÿè¤‡ç¿’ï¼š

| é¡Œè™Ÿ | ç§‘åˆ¥ | è€ƒé» | éŒ¯èª¤åŸå›  | æ­£ç¢ºç­”æ¡ˆè§£é‡‹ | é—œéµå­— | æ˜¯å¦é‡åšï¼Ÿ |
| --- | --- | --- | --- | --- | --- | --- |
| 1205 | Obs | Ectopic pregnancy diagnosis | åˆ¤æ–·å¤±èª¤ | Transvaginal US is first-line | LMP, vaginal bleeding | âœ… |

---

## âœ… ç¬¬ä¸‰ä»½ï¼š**ç¬¬ä¸€é€±å­¸ç¿’è¨ˆç•«ï¼ˆæ¯æ—¥ä»»å‹™ï¼‰**

### ğŸ”„ Week 1ï¼ˆåŸºç¤å»ºæ§‹ + é¡Œå‹ç†Ÿæ‚‰ï¼‰

| å¤©æ•¸ | ä»»å‹™å…§å®¹ | åšé¡Œé‡ | å‚™è¨» |
| --- | --- | --- | --- |
| Day 1 | é–‹å§‹å…§ç§‘æ‰“åº•ï¼ˆCV + Respiratoryï¼‰é–±è®€èƒ¸ç—›ã€å‘¼å¸å›°é›£è©•ä¼° | 50 é¡Œ | AMCQbank é¸ general med |
| Day 2 | å©¦ç”¢ç§‘ï¼šmenstrual disorders + contraceptionéŒ¯é¡Œç­†è¨˜é–‹å§‹ | 60 é¡Œ | ç”¨ Plabable çœ‹å©¦ç”¢ç²¾ç°¡èªªæ˜ |
| Day 3 | Emergency åˆæ­¥ï¼šABCDE + shock typesç·´ 5 é¡Œ timed mode | 60 é¡Œ | æ•´ç†æµç¨‹åœ– |
| Day 4 | å…’ç§‘æ‰“åº•ï¼šfever, dehydration, asthmaç™¼å±•é‡Œç¨‹ç¢‘æ•´ç† | 60 é¡Œ | éŒ¯é¡Œè¤‡ç¿’ 20 é¡Œ |
| Day 5 | ç²¾ç¥ç§‘ introï¼šmood disorders + suicide riskè¨˜æ†¶ DSM-5 é—œéµè© | 50 é¡Œ | æ¸¬é©—è‡ªæˆ‘è¨ºæ–· vs éŒ¯èª¤ |
| Day 6 | æ¨¡æ“¬å°è€ƒï¼ˆ50 é¡Œï¼‰+ å…¨é¢éŒ¯é¡Œè¤‡ç¿’è¨˜éŒ„éŒ¯é¡ŒåŸå›  | 50 é¡Œ | å¯ä½¿ç”¨ AMCQbank mini mock |
| Day 7 | å›é¡§æœ¬é€±ç­†è¨˜ + äº¤éŒ¯ç§‘åˆ¥è¤‡ç¿’ï¼ˆObs + Pedsï¼‰ | 40 é¡Œ | è‡ªè£½ quiz å°æ¸¬é©— |
